Clinical trials
Mild Alzheimer Disease clinical trials
Below are recruiting mild alzheimer disease clinical trials, each written for real people, not researchers. We’re tracking 295 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06585384RecruitingPhase 1
Safety of etanercept with contrast ultrasound for Alzheimer's
This study tests whether combining a drug called etanercept with repeated contrast ultrasound is safe for people with mild Alzheimer's. It aims to see if this approach can help slow the disease.
ParisAges 50–85 - NCT06732128Recruiting
Nature virtual reality for depression in Alzheimer's disease
This trial tests whether a virtual reality nature experience can help improve mood in people with early-to-moderate Alzheimer's disease. Participants will use a VR headset and a few apps at home, with a caregiver present, over several sessions.
Toronto, OntarioAges 50 years+ - NCT06793735Recruiting
Virtual reality app for memory and thinking problems
This trial tests a virtual reality app you can use at home to help with early memory or thinking problems. It may be an option if you have mild cognitive impairment or notice your thinking is slowing down.
Messina, ItalyAges 40–80 - NCT06841848Recruiting
Eye camera test for early Alzheimer's
This study is testing a new eye camera to see if it can help find early signs of Alzheimer's disease. It is for people aged 55 and older who either have mild to moderate Alzheimer's or do not have Alzheimer's.
Rome, ItalyAges 55 years+ - NCT06874231Recruiting
Brain connectivity marker for Alzheimer's disease
This study uses brain scans to find a marker for Alzheimer's disease. It is looking for people with normal memory, mild memory problems, or mild Alzheimer's, and who can undergo a spinal tap and MRI.
Stockholm, SolnaAges 40–85 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT07031687Recruiting
A new brain stimulation study for early Alzheimer's
This study tests a non-invasive brain stimulation method (temporal interference stimulation) to see if it can improve memory in people with early signs of Alzheimer's disease. It aims to understand how the stimulation affects brain function.
Sanya, HainanAges 60–80 - NCT07142954RecruitingPhase 3
Alzheimer's research study for healthy people
This study is looking at healthy people with no memory concerns to better understand early signs of Alzheimer's disease. You would provide samples and do thinking tests, but you won't take any experimental medicines.
Houston, TexasAges 55–75 - NCT07208344RecruitingEarly Phase 1
Umbilical cord blood infusion for Alzheimer's disease
This early-phase study tests whether infusing donated umbilical cord blood (a source of young immune cells) can help slow Alzheimer's disease. It is for people aged 50–75 with mild to moderate Alzheimer's who have a caregiver and are otherwise generally healthy.
Hefei, AnhuiAges 50–75 - NCT07294885Recruiting
Lymphatic surgery for Alzheimer's disease
This study tests a surgical procedure to connect lymph vessels in the neck to veins, which may help clear waste from the brain in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It is for patients who have not improved after at least 3 months of standard care.
ShenyangAges 50–80 - NCT02414347Recruiting
Tau PET scan study for Alzheimer’s disease
This study uses a PET brain scan with a small injected tracer to look for “tau” protein changes linked to Alzheimer’s disease. It may help researchers better understand how tau appears in people who are cognitively normal or have mild dementia.
St Louis, MissouriAges 18 years+ - NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT06924359Recruiting
Eye scans and blood tests for early Alzheimer's detection
This study uses special eye scans and blood tests to find early signs of Alzheimer's disease. It aims to detect the disease before memory loss becomes severe, so treatment can start sooner.
BeijingAges 50 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT07324161Recruiting
Magnetic Brain Stimulation for Alzheimer's Disease
This trial tests whether a non-invasive magnetic brain stimulation treatment (TMS) can help people with mild to moderate Alzheimer's disease. You would receive the treatment and be monitored for safety and benefit.
Fuzhou, FujianAges 50–90 - NCT07632755Recruiting
Memory Training Using Movement for Early Alzheimer's Disease
This study tests whether learning memory strategies through physical movement and motor activities can help people with early Alzheimer's disease improve their memory. Researchers will compare people with early Alzheimer's to healthy older adults to see if this approach is effective.
GrenobleAges 60 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Miami, FloridaAges 50 years+ - NCT04335994Recruiting
Home sleep testing for people with memory trouble
This study looks at how well home sleep apnea testing works for people with cognitive impairment (memory/thinking problems) to help improve outcomes. You may be asked to do a home sleep test (and possibly an in-lab test) and will involve a caregiver if needed.
Toronto, OntarioAges Any age - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85 - NCT06595511Recruiting
Combined sound, light, and games for Alzheimer's
This study tests a new approach combining special audio-visual stimulation (at 40 Hz) with cognitive games to see if it can help people with Alzheimer's disease. It also includes a group of healthy older adults for comparison.
Istanbul, BeykozAges 60–86 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85
Hear when a new Mild Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild alzheimer disease?
- Yes. Clin2 currently lists 295 recruiting mild alzheimer disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild alzheimer disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild alzheimer disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.